作者
George Vaiopoulos,Ioannis Michelakis,Pelagia Katsimbri,Kyriaki Lampadaki,Dimitrios Katsifis,Elena Sabatakaki,Dimitrios D. Tseronis,Konstantina Zoupidou,Alexander Katoulis,Evangelia Papadavid
摘要
PPAC, the first dual care clinic in Greece for psoriasis (PsO) and psoriatic arthritis (PsA) patients, has been based at Attikon General University Hospital, where dermatologists and rheumatologists cooperate and provide care for patients with severe, recalcitrant disease, and multiple comorbidities [1]. At the joint PPAC clinic, we have the advantage of testing the efficacy of bimekizumab in a case series of PsO patients with recalcitrant PsA with peripheral and axial manifestations who failed several previously available biologic treatments, including interleukin (IL)-17A and IL-23 inhibitors from April 1, 2023, to December 31, 2023, prior to the official approval of bimekizumab in PsA [2, 3]. This study was carried out in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. All study participants gave informed consent. Successfully switching to bimekizumab in recalcitrant PsO patients who previously have received other IL-17A or 23 inhibitors has been investigated in several studies [4]. However, there is only one small case series on the efficacy of switching biologics within the same class or from IL-23 inhibitors in patients with recalcitrant PsA [5]. The demographic and baseline clinical characteristics, as well as treatment outcomes of six patients, are summarized in Table 1: 5/6 with peripheral joint involvement manifesting as polyarthritis, 1/6 with axial participation, 4/6 with nail involvement, 1/6 with scalp psoriasis, 3/6 were treatment naïve, and 3/6 patients were bioexperienced and switched to bimekizumab due to secondary failure in both skin and joint involvement, from another IL-17A inhibitor (ixekizumab), IL-23 p19 blocker guselkumab and upadacitinib. Evaluation of absolute PASI (aPASI), Disease Activity Index for Psoriatic Arthritis (DAPSA), and Axial Spondyloarthritis Disease Activity Score (ASDAS) at Week 24 were the primary endpoints. PASI, DAPSA, ASDAS, PGA, and ΔPASI 75/90/100 were significantly improved at Week 24 (Figure 1a,b). All patients reached ΔPASI 75 and ΔPASI 90 at Week 24, whereas 5 out of 6 presented PASI < 3. The quick onset of action of bimekizumab (mean aPASI from 11.67 was reduced to 0.43 at Week 24, respectively) drags along DLQI (mean value of 17.17 at baseline to 2 at Week 24, respectively). Joint manifestations also presented a significant improvement but slower than skin manifestations (mean baseline DAPSA of 23.9 was reduced to 12.42 after 16 weeks and further decreased at a mean value of 6 up to Week 24). At Week 24, 3 out of 5 patients with peripheral arthritis achieved remission (DAPSA ≤ 4), and in the patient with only axial involvement, baseline ASDAS was reduced from 2.5 to 1.4. Bioexperienced patients had significantly higher DAPSA values at treatment start, while no differences in PASI score or other clinical characteristics could be demonstrated between bio-naïve and bio-experienced patients. All patients reached the 24-week observation endpoint, and no major safety signals responsible for drug discontinuation were recorded. No statistically significant differences were found in terms of clinical response in both skin and joint involvement regarding body mass index (BMI), smoking habits, and comorbidities. Despite the small sample size, it seemed that patients with disease onset at earlier age/longer disease duration had lower rates of achieving PASI < 3 at Weeks 16 and 24 and attaining PASI75 at Week 4. Our data confirm the efficacy and safety of bimekizumab in treating PsO and PsA patients recalcitrant to other cytokines inhibitors, IL-17A and IL-23 p19. The majority of patients achieved clear or almost clear skin and significant improvement of arthritis, starting from Week 4, with a maximal effect at Week 24. The small sample size does not allow the comparison between bio-naive and bio-experienced patients, however, bimekizumab was proven efficacious in both skin and joint manifestations regardless of previous treatment status, confirming the results from clinical trials and real-world studies [2-5]. Despite the relatively short follow-up time, this study exerts the advantages of PPAC to a better and more sustainable treatment of difficult cases with PsA/PsO. Long-term real-life studies are important to further evaluate the safety and efficacy of bimekizumab in PsA treatment. The authors declare no conflicts of interest.